Outcomes of Busulfan, Fludarabine, and 400 cGy Total Body Irradiation Compared With Busulfan and Fludarabine Reduced-Intensity Conditioning Regimens for Allogeneic Stem Cell Transplantation in Adult Patients With Hematologic Diseases: A Single-Center Experience

被引：3

作者：

Alkhaldi, Hanan ^{[1
,2
]}

Goloubeva, Olga ^{[1
]}

Rapoport, Aaron P. ^{[1
,2
]}

Dahiya, Saurabh ^{[1
,2
]}

Pang, Yifan ^{[3
]}

Ali, Moaath Mustafa ^{[1
,2
]}

Hardy, Nancy M. ^{[1
,2
]}

Mohindra, Pranshu ^{[1
,2
]}

Bukharia, Ali ^{[1
,2
]}

Lutfia, Forat ^{[1
,2
]}

Sanchez-Petitto, Gabriela ^{[1
,2
]}

Molitoris, Jason ^{[1
,2
]}

Samanta, Santanu ^{[1
,2
]}

Li, Xin ^{[1
]}

Toth, Tara ^{[1
]}

Landau, Mindy ^{[1
]}

Hodges, Susan ^{[1
]}

Nishioka, Jennifer ^{[1
]}

Ruehle, Kathleen ^{[1
]}

Ridge, Linda ^{[1
]}

Gahres, Natalie ^{[1
]}

Kocoglu, Mehmet H. ^{[1
,2
]}

Atanackovic, Djordje ^{[1
,2
]}

Malinou, Justin N. ^{[1
,2
]}

Yared, Jean A. ^{[1
,2
,4
]}

机构：

[1] Univ Maryland, Marlene & Stewart Greenebaum Comprehens Canc Ctr, Baltimore, MD 21201 USA

[2] Univ Maryland, Dept Med, Sch Med, Baltimore, MD USA

[3] NHLBI, NIH, Bethesda, MD USA

[4] Univ Maryland, Greenebaum Comprehens Canc Ctr, 22 S Greene St, Baltimore, MD 21201 USA

来源：

TRANSPLANTATION PROCEEDINGS | 2023年 / 55卷 / 01期

关键词：

ACUTE MYELOID-LEUKEMIA; VERSUS-HOST-DISEASE; LOW-DOSE TBI; EUROPEAN GROUP; WORKING PARTY; BLOOD; MALIGNANCIES; MORTALITY; AML;

D O I：

10.1016/j.transproceed.2022.10.061

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Background. Reduced intensity conditioning (RIC) regimens decrease the risk for nonrelapse mortality (NRM) in adult patients undergoing allogeneic hematopoietic stem cell transplantation for hematologic malignancies but increase the risk for relapse. The aim of this study was to compare the outcomes of fludarabine-total body irradiation (TBI) with fludarabine among patients with hematologic diseases. Patients and Methods. This retrospective study of 137 patients with different hematologic malignancies compared the outcomes of 63 patients who received a conventional RIC regimen with 2 days of IV busulfan (3.2 mg/kg/d pound 2 days) and fludarabine with 74 patients who received the same regimen plus 400 cGy of fludarabine and busulfan (FB)-TBI divided in 2 doses over 1 day (200 cGy BID). Median follow-up was 4.62 years. Results. The donors were either HLA-matched siblings (36%) or HLA-matched unrelated donors (64%). The FB-TBI showed trends toward improvement in progression-free survival (PFS) and overall survival (OS) over FB (5-year PFS rates 50% vs 34%, P = .06, and 5-year OS rate 53% vs 39%, P = .13). Acute graft-vs-host disease (aGVHD), relapse, and NRM were similar between the 2 groups. The 5-year cumulative incidence of chronic GVHD (cGVHD) was lower in the FB-TBI group compared with the FB group (29% vs 52%, P = .003). Multivariable analysis revealed that grade III-IV aGVHD was the only independent risk factor for worse OS (P = .001) in both groups. A high disease risk index was possibly associated with inferior OS (P = .07) in both groups. Conclusions. The FB-TBI is a safe and effective intensified RIC regimen for adult patients with hematologic malignancies. It predicted a lower risk for cGVHD and showed possibly improved PFS and OS compared with FB.

引用

页码：214 / 224

页数：11

共 50 条

[31] Retrospective comparison of hematopoietic stem cell transplantation following reduced-intensity conditioning with fludarabine/low-dose melphalan plus 4 Gy TBI versus fludarabine/busulfan plus 4 Gy TBI [J].

Yamada, Yuta ;

Ikegawa, Shuntaro ;

Najima, Yuho ;

Atsuta, Yuya ;

Konuma, Ryosuke ;

Adachi, Hiroto ;

Wada, Atsushi ;

Kishida, Yuya ;

Konishi, Tatsuya ;

Nagata, Akihito ;

Kaito, Satoshi ;

Nagata, Ryohei ;

Noguchi, Yuma ;

Marumo, Atsushi ;

Mukae, Junichi ;

Inamoto, Kyoko ;

Toya, Takashi ;

Igarashi, Aiko ;

Kobayashi, Takeshi ;

Sakamaki, Hisashi ;

Ohashi, Kazuteru ;

Doki, Noriko .

INTERNATIONAL JOURNAL OF HEMATOLOGY, 2022, 115 (02) :244-254

[32] Fludarabine/busulfan versus fludarabine/total-body-irradiation (2 Gy) as conditioning prior to allogeneic stem cell transplantation in patients (≥60 years) with acute myelogenous leukemia: a study of the acute leukemia working party of the EBMT [J].

Heinicke, Thomas ;

Labopin, Myriam ;

Polge, Emmanuelle ;

Niederwieser, Dietger ;

Platzbecker, Uwe ;

Sengelov, Henrik ;

Choi, Goda ;

Cornelissen, Jan ;

Blaise, Didier ;

Kuball, Jurgen ;

van Gorkom, Gwendolyn ;

Schaap, Nicolaas ;

Potter, Victoria ;

Paul, Franciane ;

Savani, Bipin N. ;

Nagler, Arnon ;

Mohty, Mohamad .

BONE MARROW TRANSPLANTATION, 2020, 55 (04) :729-739

[33] Allogeneic Haematopoietic Stem Cell Transplantation Using Reduced-Intensity Fludarabine, Busulfan and Anti-T-Lymphocyte Globulin With Strategic Donor Lymphocyte Infusion in Older Patients With Myeloid Malignancy [J].

Armstrong, Chris ;

Conneally, Eibhlin ;

Flynn, Catherine ;

Browne, Paul ;

Chonghaile, Mairead Ni ;

Galligan, Carmel Ann ;

Foy-Stones, Hayley ;

Gardiner, Nicola ;

Lee, Greg ;

Orfali, Nina .

EUROPEAN JOURNAL OF HAEMATOLOGY, 2025, 115 (01) :36-45

[34] Busulfan with 400 centigray of total body irradiation and higher dose fludarabine: An alternative regimen for hematopoietic stem cell transplantation in pediatric acute lymphoblastic leukemia [J].

Gharial, Jaspreet ;

Guilcher, Gregory ;

Truong, Tony ;

Shah, Ravi ;

Desai, Sunil ;

Rojas-Vasquez, Marta ;

Kangarloo, Bill ;

Lewis, Victor .

PEDIATRIC BLOOD & CANCER, 2024, 71 (04)

[35] Single Daily Busulfan Dosing for Infants with Nonmalignant Diseases Undergoing Reduced-Intensity Conditioning for Allogeneic Hematopoietic Progenitor Cell Transplantation [J].

Ward, Jessica ;

Kletzel, Morris ;

Duerst, Reggie ;

Fuleihan, Ramsay ;

Chaudhury, Sonali ;

Schneiderman, Jennifer ;

Tse, William T. .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2015, 21 (09) :1612-1621

[36] Reduced-Intensity Conditioning with Fludarabine, Melphalan, and Total Body Irradiation for Allogeneic Hematopoietic Cell Transplantation: The Effect of Increasing Melphalan Dose on Underlying Disease and Toxicity [J].

Chen, George L. ;

Hahn, Theresa ;

Wilding, Gregory E. ;

Groman, Adrienne ;

Hutson, Alan ;

Zhang, Yali ;

Khan, Usman ;

Liu, Hong ;

Ross, Maureen ;

Bambach, Barbara ;

Higman, Meghan ;

Neppalli, Vishala ;

Sait, Sheila ;

Block, AnneMarie W. ;

Wallace, Paul K. ;

Singh, Anurag K. ;

McCarthy, Philip L. .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (04) :689-698

[37] Prognostic impact of melphalan dose and total body irradiation use in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation with reduced-intensity conditioning [J].

Harada, Kaito ;

Yanada, Masamitsu ;

Machida, Shinichiro ;

Kanamori, Heiwa ;

Onizuka, Makoto ;

Ozawa, Yukiyasu ;

Kobayashi, Hikaru ;

Sawa, Masashi ;

Katayama, Yuta ;

Ohashi, Kazuteru ;

Kanda, Junya ;

Ichinohe, Tatsuo ;

Atsuta, Yoshiko ;

Yano, Shingo .

LEUKEMIA & LYMPHOMA, 2019, 60 (06) :1493-1502

[38] Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission [J].

Lee, Kyoo-Hyung ;

Lee, Je-Hwan ;

Lee, Jung-Hee ;

Kim, Dae-Young ;

Park, Han-Seung ;

Choi, Eun-Ji ;

Ko, Sun-Hye ;

Seol, Miee ;

Lee, Young-Shin ;

Kang, Young-A ;

Jeon, Mijin ;

Baek, Seunghyun ;

Kang, You-Lee ;

Kim, Sung-Han ;

Yun, Sung-Cheol ;

Kim, Hawk ;

Jo, Jae-Cheol ;

Choi, Yunsuk ;

Joo, Young -Don ;

Sung-Nam Lim .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2017, 23 (09) :1555-1566

[39] Total body irradiation plus fludarabine compared to busulfan plus fludarabine as "reduced-toxicity conditioning" for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acute Leukemia Working Party of the EBMT [J].

Giebel, Sebastian ;

Labopin, Myriam ;

Sobczyk-Kruszelnicka, Malgorzata ;

Stelljes, Matthias ;

Byrne, Jenny L. ;

Fegueux, Nathalie ;

Beelen, Dietrich W. ;

Rovira, Montserrat ;

Spyridonidis, Alexandros ;

Blaise, Didier ;

Bornhaeuser, Martin ;

Karadogan, Ihsan ;

Savani, Bipin N. ;

Nagler, Arnon ;

Mohty, Mohamad ;

Martin, Sonja ;

Chevallier, Patrice ;

Neubauer, Andreas ;

Damaj, Gandhi ;

Koc, Yener ;

Ganser, Arnold ;

Collin, Matthew ;

Yakoub-Agha, Ibrahim ;

Ozdogu, Hakan ;

Araujo, Mercedes Colorado ;

Itala-Remes, Maija ;

Orchard, Kim ;

Isaksson, Cecilia ;

Bethge, Wolfgang ;

Martin, Hans ;

Aljurf, Mahmoud ;

Faber, Edgar ;

Caballero, Dolores ;

Zak, Pavel ;

Leleu, Xavier ;

Bay, Jacques-Olivier ;

Rohrlich, Pierre-Simon ;

Kroeger, Nicolaus ;

Huynh, Anne ;

Schaefer-Eckart, Kerstin ;

Milpied, Noel ;

Lenhoff, Stig ;

Ho, Aloysius ;

Lopez, Jose Luis Bello ;

Mordini, Nicola ;

Lioure, Bruno ;

Halaburda, Kazimierz ;

Olivieri, Attilio ;

Gedde-Dahl, Tobias ;

Protheroe, Rachel .

BONE MARROW TRANSPLANTATION, 2021, 56 (02) :481-491

[40] Study of Kidney Function Impairment after Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation. A Single-Center Experience [J].

Pinana, Jose Luis ;

Valcarcel, David ;

Barba, Pere ;

Moreno, Estela ;

Suredo, Anna ;

Vega, Monica ;

Delgado, Julio ;

Briones, Javier ;

Brunet, Salut ;

Sierra, Jorge .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2009, 15 (01) :21-29

← 1 2 3 4 5 →